Plasma-derived products Information for patients

Similar documents
Maternity Services Intravenous iron therapy Information for women

Carriers of Haemophilia Information for patients

Haematology Mycophenolate Mofetil Information for patients

INTRAVENOUS IRON THERAPY

Adrenaline challenge for Long QT Syndrome (LQTS) Information for patients

Iron treatment for people with chronic kidney disease (CKD)

Ajmaline challenge for Brugada Syndrome Information for patients

Tranexamic acid. Information for parents and carers

Bevacizumab (Avastin ) treatment for Neurofibromatosis Type 2 (NF2) Information for patients

Food allergies and eczema

Treating kidney diseases with rituximab. Information for patients

Red blood cell transfusion

Oxford Transplant Centre. Live donor kidney transplantation what if we are not a match?

Maternity. Migraine in pregnancy Information for women

Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients

Outpatient Pain Service. Medial branch block injections Information for patients

Privigen solution for infusion

Head and Neck Oncology A guide to using your nebuliser Information for patients

Video swallow examination

Oxford Kidney Unit A guide to conservative kidney management. Information for Healthcare Professionals

Oxford Kidney Unit Your blood pressure and dialysis Information for patients

Catheter ablation for ventricular tachycardia (VT) for structural heart disease. Information for patients

Pain relief after your child s day case surgery

Aural Care, West Wing Welcome to the Aural Care Service

Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

Ocular Inflammation Service, Oxford Eye Hospital. Steroid injections. Information for patients

Tolvaptan (Jinarc ) for Adult Polycystic Kidney Disease (ADPKD)

Oxford Kidney Unit. Treatment options for chronic kidney disease A brief overview

Azithromycin and Chronic Obstructive Pulmonary Disease (COPD) Information for patients

A Patient s Guide to Blood Components and Products

Stereotactic ablative body radiotherapy to the lung Information for patients

Trauma Department. Caring for Your Cast. Information for patients

Bexarotene for cutaneous T-cell lymphoma (CTCL) Information for patients

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Physiotherapy on the Intensive Care Unit. Information for patients, their family and carers

Emergency Department Using Elbow Crutches Instructions for patients

Children s Allergy Clinic. General food challenges at home Information for parents and carers

(Whole Central Nervous System)

The Children s Hospital, Oxford Sedation for clinical procedures Information for parents and carers

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

Transoesophageal echocardiogram (TOE)

Suspected CANcer (SCAN) Pathway Information for patients

A Patient s guide to. Blood Transfusions and Human Tissue Transplant

Regional anaesthesia peripheral nerve blocks for upper limb surgery

Plasma exchange. Information for patients Sheffield Kidney Institute (Renal Unit)

Fit, faint or funny turn? Information for people who may have had a first seizure

Package Leaflet: Information for the User

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Methotrexate for inflammatory bowel disease: what you need to know

Propranolol treatment for infantile haemangioma

Rituximab treatment in autoimmune blistering diseases

Immune Thrombocytopenic Purpura (ITP)

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

Traztuzumab (Herceptin)

MIBG Scan. Nuclear Medicine Department Children s Hospital, John Radcliffe Hospital. Information for parents and carers. Oxford University Hospitals

Emergency Department. Advice after your child s head injury Information for parents and carers

VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection

Do not g ive this drug if your child has an infection or any inflammation.

Tracheostomy. Information for patients and relatives

Before you are given Privigen

Chronic Kidney Disease due to Diabetes (Diabetic Nephropathy)

Package leaflet: Information for the user

BLOOD TRANSFUSIONS. Answers. To Your. Questions

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

Package leaflet: Information for the user

BLOOD TRANSFUSIONS. Answers. To Your. Questions

Temporary Sacral Nerve Stimulator (SNS)

Vinblastine (Lymphoma)

Answers. To Your. Questions

Body changes, washing, clothing and returning to normal activities after your stoma surgery

Oxford University Hospitals. NHS Trust. Oral and Maxillofacial Surgery Jaw surgery. Information for patients

VIVAXIM. Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine. Consumer Medicine Information

What do I need to tell my doctor BEFORE I take this drug? If you have an allerg y to ofatumumab or any other part of this drug.

Intravenous anti-cancer treatment

Methotrexate. Information for patients. Paediatric Rheumatology. Feedback

MERIEUX INACTIVATED RABIES VACCINE (MIRV) Rabies Vaccine

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

Maternity. Physical Activity throughout Pregnancy Information for Women

Children s Allergy Clinic General food challenges at home. Information for parents

Cyclophosphamide Treatment (To be used in conjunction with the Shared Care Blood Test Monitoring Card)

Interventional Radiology (IR)

Pulmonary Embolism (PE)

A guide to hydroxycarbamide (hydroxyurea)

Nivolumab. Nivolumab

High dose melphalan conditioning for autologous transplant (inpatient) Palatine treatment centre

Brentuximab vedotin. Brentuximab vedotin

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

X-Plain Blood Transfusion Reference Summary

Tocilizumab Tocilizumab

Treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin

Your guide to the HPV vaccine

Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge

Temozolomide Chemotherapy -

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)

Robotic-assisted lingual tonsillectomy for sleep apnoea

what you need flu. Protect yourself and others.

Transcription:

Plasma-derived products Information for patients

page 2

You have been given this leaflet as your doctor has advised you that you may require plasma-derived products as a treatment for your bleeding disorder. This leaflet explains what plasma-derived products are, how you will receive them, and any risks or side effects. What is plasma? Plasma is the fluid part of blood, which makes up the bulk of its volume. Blood is made up of four separate components, each of which performs a different function. They are: red blood cells these carry oxygen around the body and remove carbon dioxide white blood cells which help the body fight infection platelets these are tiny cells that help the blood to clot plasma a yellow fluid that transports blood cells and platelets around the body. It contains a number of substances, including minerals, salts, hormones and proteins Clotting factors are proteins found in plasma which help control bleeding. They work together with platelets to make sure the blood clots effectively. These can be used to treat bleeding disorders. If you are deficient in a clotting factor your blood may not clot properly. This may cause any bleeding you experience to last longer. page 3

What are plasma-derived products? Plasma-derived products include clotting factor concentrates and frozen plasma. Plasma-derived products are made from donated human blood, from which the plasma or clotting proteins are separated or removed and made into clotting factor concentrates (specific clotting proteins, liquid or freeze dried as a powder) or fresh frozen plasma. These are then used to treat a variety of conditions, including bleeding disorders. Sometimes plasma is mixed or pooled when making certain types of plasma-derived products. This means the plasma is donated from a number of different people. Which plasma-derived products will I receive? A number of different plasma-derived products may be used to treat bleeding disorders. Each specific plasma-derived product contains different clotting proteins. Your doctor will advise you which product is best suited to treat your condition, to stop or reduce the risk of bleeding. You can ask for further specific information once the doctor has chosen the appropriate product for you. page 4

How will I receive the plasma-derived products? All plasma-derived products are given intravenously (through a vein in your arm) by either a nurse or doctor whilst you are in hospital, unless you have received training to treat yourself at home. The time it takes to administer the treatment or the number of doses you might need varies for each different product. Your doctor or nurse will be able to give you more information depending on the treatment you will need. Risks and side effects Virus safety Treatments that are made from human blood or plasma are taken through certain steps to reduce the chance of infections being passed on through the plasma-derived product. These include: careful selection and screening of blood and plasma donors, to make sure those at risk of carrying infections are excluded testing each donation and pooled plasma for signs of virus or infections, to make sure they are safe to use using heat or chemical processes to inactivate or remove viruses. These measures are considered effective for screening out viruses such as HIV and hepatitis A, B and C. When you receive a plasma-derived product you will also be checked for signs of these viruses with a blood test at your routine follow-up clinic. Although the plasma-derived product is thoroughly screened, the risk of passing on infection cannot be totally excluded. This also applies to any unknown or new viruses, or other types of infections. page 5

It is important to note that there is also a risk of passing on a virus known as parvovirus B19. Parvovirus B19 infection maybe serious for: pregnant women (as there is a risk of infection to the unborn child) people with a weakened immune system or with an increased production of red blood cells due to certain types of anaemia (such as sickle cell anaemia or haemolytic anaemia). Your doctor may recommend that you consider being vaccinated against hepatitis A and B if you need plasma-derived products regularly or as part of your treatment. There are currently no vaccinations for hepatitis C, HIV or parvovirus B19. Side effects Some people can experience problems or allergic reactions related to the treatment. Anaphylaxis is a rare but severe allergic reaction. Signs of an allergic reaction include: swelling of your face or lips itching rash or hives (raised red marks on the skin) wheezing or shortness of breath. You will be closely monitored during the infusion of the treatment for any signs or symptoms of a reaction. If you experience any of these side effects let you doctor or nurse know immediately. page 6

Further advice If you have any worries or questions about using plasma-derived products to treat your bleeding disorder, please contact the Haemophilia and Thrombosis Centre at the Churchill Hospital. Ask to speak to a haemophilia doctor or nurse. Tel: 01865 225 316 (9.00am to 5.00pm, Monday to Friday) Tel: 01865 741 166 After 5.00pm and at weekends please ask for the on-call specialist registrar in haematology. page 7

If you have a specific requirement, need an interpreter, a document in Easy Read, another language, large print, Braille or audio version, please call 01865 221 473 or email PALS@ouh.nhs.uk Authors: Sayma Raza-Burton, Haemophilia Specialist Nurse Practitioner Dr Nicola Curry, Consultant Haematologist March 2017 Review: March 2020 Oxford University Hospitals NHS Foundation Trust Oxford OX3 9DU www.ouh.nhs.uk/information OMI 14442P